Forty Seven, Inc. Securities Litigation

If you purchased a significant amount of shares of Forty Seven, Inc. (NASDAQ: FTSV), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:Forty Seven, Inc.
Date Filed:March 17th, 2020
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:March 2nd, 2020
Class End Date:March 17th, 2020

According to the Complaint, Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University.

This action stems from a proposed transaction announced on March 2, 2020, pursuant to which Forty Seven, Inc.
will be acquired by Gilead Sciences, Inc.

On March 1, 2020, Forty Seven's Board of Directors caused the Company to enter into an agreement and plan of merger with Gilead.

On March 10, 2020, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Forty Seven, Inc.

 
First Identified Complaint

Joseph Post, et al. v. Forty Seven, Inc., et al.

Date Filed:March 17th, 2020
Class Period Start:March 2nd, 2020
Class Period End:March 17th, 2020
First Identified Complaint Filings
#Document TitleFiling Date